GREENCELL INCORPORATED (OTCBB: GCLL)
GreenCell Inc., founded in 2009 and headquartered in Orlando, Florida is engaged in a joint venture with SenCer Inc. to develop, commercialize, and market SenCer's UltraTemp™ ceramic composite materials for home and transportation applications.
MUNDUS GROUP INCORPORATED (OTC: MNDP) "Up 126.67% in morning trading"
The Mundus Group, Inc. is an advanced aerospace technology consortium providing patented Vertical Take Off and Landing (VTOL) technology for experimental aircraft and Unmanned Air Vehicles (UAV) since 1990 through its fully owned VTOL division, Roadable Aircraft International (RAI). Mundus is at the cutting edge of jet turbine-ducted fan technology and fuses state of the art design engineering and a prototyping facility with computer assisted auto flight technologies, Remote Controlled (RC) and composite technologies industry segments. From US Navy co-developed UAVs for aerial observation and environmental testing to advanced VTOL aerospace technology for civilian and military uses, Mundus Group, Inc. is developing revolutionary products with global potential for change that offers economic protection and growth opportunities for investors.
MELA SCIENCES INCORPORATED (NASDAQ: MELA) "Up 59.75% in morning trading"
MELA Sciences is a medical technology company focused on developing MelaFind®. MelaFind® is a non-invasive and objective multi-spectral computer vision system designed to aid physicians in the detection of early melanoma from among clinically atypical (those having one or more clinical or historical characteristics of melanoma, such as asymmetry, border irregularity, color variegation, diameter greater than 6 millimeters, evolving, patient concern, regression, and ugly duckling) cutaneous pigmented lesions that are non-ulcerated, not bleeding, and less than 2.2 centimeters in diameter, when a physician chooses to obtain additional information before making a final decision to biopsy to rule out melanoma.
MARINA BIOTECH INCORPORATED (NASDAQ: MRNA) "Up 14.52% in morning trading"
Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs — in bladder cancer and malignant ascites. Marina Biotech entered into an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies that together provide superior therapeutic options for patients.
About OTCPicks.com
OTCPicks.com, one of the leading penny stock Web sites, presents its daily Stocks to Watch and Midday Market Movers every weekday. In addition to all the latest penny stock news, OTCPicks also offers daily newsletters, unique commentaries and free profiles, alerts and investing tips.
The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily penny stock alerts CLICK HERE.
Disclosure: OTCPicks.com and affiliates have been compensation nine thousand dollars by a third party (Emerging Markets Consulting) for this current GCLL advertising and promotional program.
